Edgewise Therapeutics, Inc.

NASDAQ:EWTX

Biotechnology

Healthcare
$41.37 +3.19%

+$1.11 today

Market cap
$4.45B
Beta
0.30
P/E (TTM)
-21.9
EPS (TTM)
-$1.64
52W Low $12.15High $40.77

Volume 0.87M

Average 1.32M

EWTX Short-term Debt

Borrowings and the current portion of long-term debt due within one year.

Edgewise Therapeutics, Inc.NASDAQ: EWTX

Short-term Debt · Q3 FY2026 · quarter ended Sep 2026

Short-term debt remains negative

Q3 FY2026 short-term debt was $1.03M, compared with $0 a year earlier.

Context

  • Short-term debt amounted to 0.1% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
  • Short-term debt increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$1.03M— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoSep 2025
$0— since
Short-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Short-term Debt history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Short-term Debt vs competitors

How EWTX compares with its peers on the latest reported figures

  • EWTX's Sep 2026 short-term debt of $1.03M is the 7th highest of the 10 companies compared; the peer median is $2.19M.
  • Short-term debt amounts to 0.1% of total assets for EWTX, versus a peer median of 0.5%.
EWTX Competitors Peer median
Short-term Debt for EWTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
PTCTPTC Therapeutics, Inc.Jun 2026$55.45M —+99.1%1.7%
CAPRCapricor Therapeutics, Inc.Mar 2026$7.18M +752.7%+74.5%2.2%
DYNDyne Therapeutics, Inc.Jun 2026$5.37M ——0.5%
STOKStoke Therapeutics, Inc.Mar 2026$2.43M ——0.5%
SLDBSolid Biosciences Inc.Mar 2026$2.19M ——0.5%
LRMRLarimar Therapeutics, Inc.Mar 2026$1.06M -3.5%—0.5%
EWTXEdgewise Therapeutics, Inc.Sep 2026$1.03M ——0.1%
SRPTSarepta Therapeutics, Inc.Mar 2026$0 ——0.0%
PEPGPepGen Inc.Mar 2026$0 ——0.0%
TRDAEntrada Therapeutics, Inc.Mar 2026$0 ——0.0%
Peer median (excluding EWTX) $2.19M+374.6%+86.8%0.5%

Competitors are the stored peer set for EWTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents15.57M21.99M86.1M41.67M61.15M
Short-term Investments265.22M329.95M232.3M428.5M468.96M
Net Receivables00000
Inventory00000
Other Current Assets008.6M5.31M13.28M
Total Current Assets283.77M357M327M475.48M543.39M
Property, Plant & Equipment (Net)912K9.85M12.69M11.07M9.22M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets548K251K348K262K0
Total Non-current Assets1.46M10.1M13.04M11.33M9.22M
Total Assets285.23M367.1M340.04M486.82M552.6M
Account Payables3.84M6.11M4.03M5.58M6.01M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities2.8M4.03M5.7M10.06M12.43M
Total Current Liabilities10.52M16.59M16.77M23.86M27.37M
Long-term Debt00002.98M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities329K0000
Total Non-current Liabilities329K3.8M4.43M3.74M2.98M
Total Liabilities10.85M20.39M21.21M27.6M30.35M
Common Stock5K6K7K9K10K
Retained Earnings(76.96M)(144.6M)(244.76M)(378.58M)(546.37M)
Accumulated OCI(514K)(1.36M)99K420K677K
Other Stockholders Equity00000
Minority Interest00000
Total Equity274.38M346.72M318.83M459.22M522.26M
Total Debt04.41M5.41M4.74M3.99M
Net Debt(15.57M)(17.59M)(80.68M)(36.93M)(57.16M)

Edgewise Therapeutics, Inc.

NASDAQ:EWTX

Intrinsic Alpha fair value

Locked

Current Price

$41.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.